Methsuximide

DB05246ApprovedSmall moleculeAnti-epileptic Agent

Methsuximide is a succinimide anticonvulsant that increases the seizure threshold. Primarily used for childhood absence seizures. Functions by suppressing paroxysmal spike-and-wave patterns associated with lapses of consciousness in absence seizures. It is sold by Pfizer under the name Petinutin.

Chemical structure of Methsuximide
Mechanism
Curator reviewed
Primary indication
For the control of absence (petit mal) seizures that are refractory to other drugs.Curator reviewed · 1 structured indication
Formula / weight
C12H13NO2 · 203.2371 g/mol (avg)
First approval
Canada, 2005 · United States, 1957
Also known as
alpha-Methylphensuximide · Mesuximide
Brand names
  • Celontin

Resolves to

Structure
InChIKeyAJXPJJZHWIXJCJ-UHFFFAOYSA-NSMILESCN1C(=O)CC(C)(C1=O)C1=CC=CC=C1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,662Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
5Marketed productsAcross 2 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 21 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Methsuximide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account